Positive trials in ischaemic stroke reported at ESOC 2018
NATURE REVIEWS NEUROLOGY | NATURE PUBLISHING GROUP | Published : 2018
BACKGROUND: Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population. METHODS: In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in eac..View full abstract
Awarded by National Institute of Neurological Disorders and Stroke
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Supported by grants (U01 NS062835, U01 NS056975, and U01 NS059041) from the National Institute of Neurological Disorders and Stroke. Sanofi provided clopidogrel and placebo for 75% of the patients in the trial.Dr. Johnston reports receiving grant support from AstraZeneca; Dr. Easton, receiving grant support from AstraZeneca and consulting fees from Boehringer Ingelheim; Ms. Farrant, receiving grant support from AstraZeneca; and Dr. Kim, receiving grant support from SanBio and fees for serving as a member of a data and safety monitoring board from Neuravi. No other potential conflict of interest relevant to this article was reported.